[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"angina-attacks\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:angina-attacks":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,59],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":37,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100414271","icormica---stratified-medicine-in-angina-100414271",false,"NCT04674449","iCorMicA - Stratified Medicine in Angina","International Study of Coronary Microvascular Angina (iCorMicA): a Randomised, Controlled, Multicentre Trial and Registry","iCorMicA","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. A clinical plan for invasive coronary angiography.\n3. Symptoms of angina (typical or atypical) according to the Rose- and\u002For Seattle Angina questionnaires.\n4. Able to comply with study procedures.\n5. Able to provide informed consent.\n\nExclusion Criteria:\n\n1. A non-coronary primary indication for invasive angiography (e.g. valve disease, heart failure).\n2. History of coronary artery bypass surgery.\n3. Presence of obstructive disease evident in a main coronary artery (diameter \\>2.5 mm), i.e. a coronary stenosis \\>50% and\u002For a fractional flow reserve (FFR) ≤0.80\\*.\n4. Logistical reason\\*. \\*These patients will enter a follow-up registry.","ALL","18 Years",{"count":20,"type":21},1500,"ESTIMATED","INTERVENTIONAL",[24],"NA","The iCorMicA study is a multicentre, prospective, randomised, double-blind, sham-controlled, parallel-group, end-point trial and registry. The investigators seek to determine whether stratified medical therapy guided by an adjunctive interventional diagnostic procedure (IDP) during the invasive management of patients with known or suspected angina but no obstructive coronary artery disease improves symptoms, wellbeing, cardiovascular risk and clinical outcomes.",[27,28,29,30,31,32,33,34,35,36],"Microvascular Angina","Angina, Stable","Ischemia With No Obstructive Coronary Arteries (INOCA)","Coronary Microvascular Dysfunction (CMD)","Ischaemic Heart Disease","Non-Obstructive Coronary Atherosclerosis","Coronary Artery Disease","Vasospastic Angina","Coronary; Ischemic","Angina Attacks",[38,39,40,41,42,43,44,45],"angina","microvascular angina","ischaemia with no obstructive coronary artery disease (INOCA)","stratified medicine","clinical trial","outcomes research","prognosis","health economics","RECRUITING","2026-04-03",{"date":49,"type":50},"2026-04-09","ACTUAL",{"date":52,"type":50},"2020-12-30",{"date":54,"type":21},"2030-12-31",{"name":56,"class":57},"NHS Greater Glasgow and Clyde","OTHER",39,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":66,"minAge":18,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":22,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100584527","phase-2-the-anti-anginal-effects-of-n-acetylcysteine-nac-in-patients-with-angina-and-non-obstructive-coronary-arteries-anoca-100584527","NCT06890507","The Anti-Anginal Effects of N-Acetylcysteine (NAC) in Patients with Angina and Non-Obstructive Coronary Arteries (ANOCA)","NANA","Inclusion Criteria:\n\n1. Provision of informed consent prior to any study specific procedures\n2. Female patients aged ≥18 years\n3. No obstructive CAD (defined as either absence of epicardial lesions with ≥50% luminal narrowing in any coronary artery segment on coronary angiography or normal findings on computed tomography (CT) angiogram, indicating the absence of significant stenosis) to account for chest pain symptoms.\n4. Chest pain occurring ≥3 times\u002Fweek in the preceding two weeks.\n\nExclusion Criteria:\n\n1. Known allergy to NAC or its components.\n2. Acute myocardial infarction admission within the preceding month (hospital admission for prolonged angina paint associated with a cardiac troponin level above the 99th percentile, with a subsequent rise or fall).\n3. Secondary causes of angina including:\n\ni. clinically significant anaemia (haemoglobin \\\u003C100g\u002FdL) ii. uncontrolled atrial fibrillation (ventricular response rate \\>108bpm) iii. haemodynamically significant aortic stenosis (mean valve gradient ≥40mmHg) d) Known concomitant disease with life expectance of less than 1 year. e) Abnormalities in liver function tests suggesting hepatic impairment (ALT and\u002For AST 2 x upper limit of normal (ULN) or ALP 2 x ULN or Bilirubin 1.5 x ULN) f) Severe renal impairment (eGFR \\\u003C30mL\u002Fmin) or on dialysis. g) Pregnancy or lactation. h) Untreated hypertension i) Unwilling, or unable, to give informed consent, including due to severe psychiatric conditions affecting informed consent process or compliance.\n\nj) History of substance abuse. k) Currently taking Chloroquine. l) Serious or unstable medical conditions that may interfere with the study, as determined by the PI.\n\nm) Concomitant participation in another clinical trial or research study (except where in the opinion of the PI, the participant could benefit from enrolling in another trial)","FEMALE",{"count":68,"type":21},25,[70],"PHASE2","The goal of this clinical trial is to determine if N-acetylcysteine (NAC) can reduce angina frequency in women with Angina with Non-Obstructive Coronary Arteries (ANOCA). It will also assess the impact of NAC on health status and quality of life. The main questions it aims to answer are:\n\n(i) Does NAC reduce the number of angina episodes per week? (ii) How does NAC affect quality of life and symptom burden in ANOCA patients? (iii) Does NAC reduce the need for short-acting nitrate use?\n\nResearchers will compare NAC to a placebo in a randomized, double-blind, placebo-controlled crossover study to determine its effectiveness.\n\nParticipants will receive treatment with NAC 600mg twice daily for 4 weeks (28 days) and matched placebo for 4 weeks (28 days) in a computer-generated random order giving a total dosing period of 8 weeks. There will be a 2-week washout between the two treatment periods.\n\nThe effectiveness of N-Acetylcysteine (NAC) will be assessed using the following measures:\n\nAngina Diary: Participants will record the frequency and severity of their angina episodes.\n\nSeattle Angina Questionnaire-7 (SAQ-7): Participants will complete this questionnaire to assess physical limitations, angina frequency, and quality of life.\n\nEuroQol 5-Dimension (EQ-5D) Questionnaire: Participants will rate their overall health and quality of life.",[36,73],"Non Obstructive Coronary Artery Disease",[75,76,77],"ANOCA","Angina with Non Obstructive Coronary Arteries","N-acetylcysteine","NOT_YET_RECRUITING","2025-03-16",{"date":81,"type":50},"2025-03-24",{"date":83,"type":21},"2025-06-01",{"date":85,"type":21},"2027-09-01",{"name":87,"class":57},"University of Adelaide",1]